An observational study in Psychiatric Disorder, sponsored by Egyptian Chinese University. Not yet recruiting. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Egyptian Chinese University · Observational
This study aims to understand the safety of antipsychotic medications and how consistently patients take these medicines in Egypt. It will involve adult patients aged 18-65 years who are receiving antipsychotic medications at participating psychiatric hospitals in Cairo.
The study will assess the side effects experienced by patients, their medication-taking habits, and their quality of life. Information will be collected through questionnaires, medical records, clinical assessments, and available laboratory test results.
The study is observational, meaning that participants will continue to receive their usual medical care, and the researchers will not assign any new treatment or medication as part of the study. Data will be collected at one point in time, without planned follow-up visits for research purposes.
The findings may help healthcare professionals better understand the side effects of antipsychotic medications, identify factors associated with medication non-adherence, and improve patient counseling and treatment monitoring. Participation is voluntary, and eligible patients will be asked to provide written informed consent. Participants' privacy and confidentiality will be protected.
1,740 studies on the registry are indexed under Mental Disorders; 348 are open to participants now.
This study's planned enrollment of 250 is above the median of 220 across 389 observational studies indexed under Mental Disorders.
Browse Mental Disorders studies →Egyptian Chinese University is the lead sponsor of 11 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
adult patients aged 18-65 years, of either sex, who are receiving antipsychotic medications at the participating psychiatric institutions in Cairo, Egypt: Okasha Institute of Psychiatry, Ain Shams University Hospital; Abbasia Hospital for Mental Health; and Heliopolis Psychiatric Hospital (Al-Matar).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Safety profile and adverse effects associated with antipsychotics use
Assessment of the safety profile and adverse effects associated with antipsychotic medication use among participating patients.
Time frame: At Baseline Day 1
Adherence to antipsychotic medication
Assessment of participants' adherence to antipsychotic medication.
Time frame: At Baseline Day 1
Prevalence of antipsychotics non-adherence
Determination of the prevalence of non-adherence to antipsychotic medication among participating patients.
Time frame: At Baseline Day 1
No study locations are listed for this record.
Plan to share: No — Data will be made available on request
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Egyptian Chinese University